- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.
The tests can detect CNP antigens and antibodies. Analysis will be performed at AHA's main laboratory in Miramar. Nanobac's laboratory in Finland will continue to service the world market after having performed thousands of such tests worldwide since the year 2000.
"This is the continuation of our new business strategy that was announced on our investor conference call three weeks ago," commented Alex Edwards Director Nanobac Pharmaceuticals. "Making our diagnostic test for CNPs available under IUO conditions will help meet the growing demand from patients and physicians throughout the country. This is the first step toward acceptance of our NB2 test as a valuable health evaluation tool and potentially a standard of care in this country."
About Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here
Nanobac Pharmaceuticals, Tampa
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New remote-controlled microrobots for medical operations July 23rd, 2016
New probe developed for improved high resolution measurement of brain temperature: Improved accuracy could allow researchers to measure brain temperature in times of trauma when small deviations in temperature can lead to additional brain injury July 23rd, 2016